Lycia Therapeutics, Inc.

expected

Oct 23, 2026

per news reports

status

Filed with SEC

The expected listing date (Oct 23, 2026) comes from news reporting, not a regulatory filing — regulators publish a filing or approval date, not the day a company starts trading. See the source. It is replaced automatically if an official date is published.

Industry

Biological Products, (No Diagnostic Substances)

Headquarters

United States

Incorporated in

Underwriters (from filing)

Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C, Guggenheim Securities, LLC, LifeSci Capital, LLC

Overview

— AI-generated from the filing, see note below

Business overview

Lycia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics aimed at degrading disease-causing extracellular proteins, particularly in autoimmune, inflammatory, and allergic diseases. Using its proprietary LYTAC platform, the company has a pipeline of therapeutic candidates designed to address limitations of existing therapies, primarily in the treatment of IgE-mediated allergic diseases, including food allergies. The firm conducts clinical trials to generate early proof of concept for its candidates, such as LCA-0061 and LCA-0062, both targeting IgE, and is exploring additional programs like LCA-0321 for Graves' disease.

Revenue model

Not disclosed in the provided filing text.

Competitive strengths

Proprietary LYTAC platform for targeted degradation of proteins
Initial positive clinical data supporting efficacy compared to existing therapies
Focused on areas with significant unmet medical needs and large patient populations

Risk factors

High degree of risk associated with clinical trials and biotechnology development
Dependence on the successful advancement of clinical programs
Potential regulatory hurdles in obtaining necessary approvals

Use of proceeds

Not disclosed in the provided filing text.

This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.

IPO details

The expected date is Oct 23, 2026. Underwriters on the deal include Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C, Guggenheim Securities, LLC, LifeSci Capital, LLC. Lycia Therapeutics, Inc. is headquartered in United States and incorporated in DE. It is classified under Biological Products, (No Diagnostic Substances).

Related IPO lists

Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Lycia Therapeutics, Inc..

Biotech IPOs United States IPOs Jefferies LLC IPOs Guggenheim Securities, LLC IPOs

Embed this company

Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.

Iframe — WordPress / Ghost / Notion / Webflow

<iframe src="https://www.discoveripo.com/embed/lycia-therapeutics" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Lycia Therapeutics, Inc. — DiscoverIPO"></iframe>

Dark by default. For a light background, use https://www.discoveripo.com/embed/lycia-therapeutics?theme=light as the src instead.

Share image — Substack, email, anywhere

https://www.discoveripo.com/ipo/lycia-therapeutics/opengraph-image

Attribution text

Lycia Therapeutics, Inc. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/lycia-therapeutics?utm_source=embed&utm_medium=text&utm_campaign=lycia-therapeutics

Track this IPO

Get emailed when Lycia Therapeutics, Inc.'s terms, price, or expected date change — no weekly noise, just this company.

Frequently asked questions

When is Lycia Therapeutics, Inc. expected to go public?

Lycia Therapeutics, Inc. is expected to list on Oct 23, 2026.

Where this data comes from

Registration statement filed with the U.S. Securities and Exchange Commission. Retrieved Oct 20, 2026.

View the original filing on SEC EDGAR →

Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public securities-regulator filings, may be incomplete or out of date, and should be verified against the original source before you act on them.